Enzyme-Responsive Nanoparticles For Targeted Accumulation And Prolonged Retention In Myocardial Infarction
- 詳細技術說明
- Researchers from UC San Diego have developed a method for targeting and retaining intravenously injected nanoparticles at the site of acute myocardial infarction. Enzyme-responsive peptide–polymer amphiphiles are assembled as spherical micellar nanoparticles, and undergo a morphological transition from spherical-shaped, discrete materials to network-like assemblies when acted upon by matrix metalloproteinases (MMP-2 and MMP-9), which are up-regulated in heart tissue post-myocardial infarction. These enzyme-responsive nanoparticles provide an efficient template for targeting the acute MI and remain in the infarct for up to 28 d post-injection. This unique approach constitutes a minimally invasive method for the delivery of a material scaffold to acutely infarcted myocardium, providing a promising approach for prolonged therapeutic delivery (e.g. peptide, small molecules, etc.) to treat an acute myocardial infarction.
- *Abstract
-
Heart failure following a myocardial infarction (MI) continues to be one of the leading causes of death. Immediately after MI, there is an initial inflammatory response with cardiomyocyte death and degradation of the extracellular matrix. This results in negative left ventricular (LV) remodeling leading to wall thinning, LV dilation, and depressed cardiac function. Several experimental approaches have been examined to inhibit this negative remodeling process. One promising direction is the use of injectable biomaterials, which can be used as stand-alone scaffolds to encourage endogenous repair or for delivering therapeutics such as cells, growth factors, or small molecules.
Early intervention of MI has the potential to slow or inhibit the progression of negative LV remodeling. To date, most therapeutic delivery strategies have involved intramyocardial biomaterial injections, although translation to acute MI patients is unlikely given the increased risk of ventricular rupture immediately post-MI. One promising, minimally invasive strategy is the systemic injection of nanoparticles. However, many of the investigated systems lack long-term retention within the MI.
- *IP Issue Date
- Oct 27, 2016
- *Principal Investigation
-
Name: Karen Christman
Department:
Name: Nathan Gianneschi
Department:
- 其他
-
State Of Development
Demonstrated proof-of-concept that the enzyme-responsive nanoparticles target, assemble, and are retained in an acute MI, thereby providing a promising approach for delivery of therapeutics immediately post-MI and obviating the need for risky intramyocardial injections. The inventors have demonstrated through study that the responsive nanoparticles are enzyme-responsive, accumulate due to upregulation of MMPs after MI, and are deliverable through both intramyocardial and IV injection.
Related Materials
Tech ID/UC Case
25782/2015-256-0
Related Cases
2015-256-0
- 國家/地區
- 美國
